Up-regulation of lncRNA IGF2-ASexpression promotes progression of colorectal cancer

doi:10.16352/j.issn.1001-6325.2025.03.0323

Abstract

Abstract: Objective To investigate the expression and clinical significance of lncRNA insulin growth factor 2 antisense IGF2-AS in colorectal cancer; To verify the biological function of IGF2-AS in cells and to screen protein molecules regulated by IGF2-AS. Methods Using bioinformatics to predict the expression and clinical significance of IGF2-AS in colorectal cancer; Using RT-qPCR to detect the expression of IGF2-AS mRNA; Using small interfering RNA to knockdown IGF2-AS; Using CCK8, Transwell assay and flow cytometry to detect proliferation, migration, and apoptosis, respectively; Using label free quantitative proteomics to screen for factors regulated by IGF2-AS; Using databases such as GenCards, OMIM, TTD, and proteomics Results screening for core targets regulated by IGF2-AS in colorectal cancer. Results Bioinformatics analysis showed that IGF2-AS was significantly upregulated in colorectal cancer(P＜0.001), its expression might be related to TNM stage (P＜0.01) and the presence of lymph node metastasis(P＜0.001); RT-qPCR Results showed that as compared to the control group, the expressionlevel of IGF2-AS mRNA was significantly up-regulated in colorectal cancer tissues (P＜0.01) and most colon cancer cells(P＜0.000 1); Clinical pathological data indicated that the expression of IGF2-AS was potentially associated with the lymph node metastasis (P＜0.05); The proliferation rate and migration rate of colorectal cancer cells transfected with IGF2-AS siRNA were significantly reduced (P＜0.000 1), and the apoptosis rate was significantly increased (P＜0.05); There were 13 proteins including KRAS, TCF7L2 and CASP3, that were potentially core targets regulated by IGF2-AS.Conclusions IGF2-AS is significantly up-regulated in colorectal cancer and may play a cancer promoting role in colorectal cancer development.

Key words: colorectal cancer, long non-coding RNA, insulin like growth factor 2 antisense(IGF2-AS)

CLC Number:

R574.6

CUI Lijiao, WU Xiu, GU Zhiwei, ZHOU Yu, YU Caiyuan. Up-regulation of lncRNA IGF2-ASexpression promotes progression of colorectal cancer[J]. Basic & Clinical Medicine, 2025, 45(3): 323-330.

References

[1] Dekker E, Tanis PJ, Vleugels JLA, et al. Colorectal cancer[J]. Lancet, 2019, 394: 1467-1480.
[2] Lin H, Guo Q, Lu S, et al. LncRNA SUMO1P3 promotes proliferation and inhibits apoptosis in colorectal cancer by epigenetically silencing CPEB3[J]. Biochem Biophys Res Commun, 2019, 511: 239-245.
[3] Buccafusca G, Proserpio I, Tralongo AC, et al. Early colorectal cancer: diagnosis, treatment and survivorship care[J]. Crit Rev Oncol Hematol, 2019, 136: 20-30.
[4] Fenocchio E. Rethinking colorectal cancer prognosis: beyond microsatellite status[J]. Lancet Gastroenterol Hepatol, 2024, 9: 585-586.
[5] Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs[J]. Cell, 2009, 136: 629-641.
[6] Morlando M, Ballarino M, Fatica A, et al. The Role of long noncoding RNAs in the epigenetic control of gene expression[J]. Chem Med Chem, 2014, 9: 505-510.
[7] Chi Y, Wang D, Wang J, et al. Long non-coding RNA in the pathogenesis of cancers[J]. Cells, 2019, 8:1015. doi: 10.3390/cells8091015.
[8] Huang J, Chen YX, Zhang B. IGF2-AS affects the prognosis and metastasis of gastric adenocarcinoma via acting as a ceRNA of miR-503 to regulate SHOX2[J]. Gastric Cancer[J]. 2020, 23: 23-38.
[9] Xiang Y, Zong QB, Liu H, et al. LncRNA IGF2-AS regulates miR-500a-3p/PPP4R1/p-VEGFR2 signalling pathway to promote thyroid carcinoma progression and tubulogenesis[J]. Clin Transl Med, 2023, 13: e1240. doi: 10.1002/ctm2.1240.
[10] Yan B, Ren Z, Sun J, et al. IGF2-AS knockdown inhibits glycolysis and accelerates apoptosis of gastric cancer cells through targeting miR-195/CREB1 axis[J]. Biomed Pharmacother, 2020, 130: 110600. doi: 10.1016/j.biopha.2020.110600.
[11] Liu B, Liu Y, Zhou M, et al. Comprehensive ceRNA network analysis and experimental studies identify an IGF2-AS/miR-150/IGF2 regulatory axis in colorectal cancer[J]. Pathol Res Pract, 2020, 216: 153104. doi: 10.1016/j.prp.2020.153104.
[12] Bao H, Guo CG, Qiu PC, et al. Long non coding RNA IGF2-AS controls hepatocellular carcinoma progression through the ERKMAPK signaling pathway[J]. Oncol Lett, 2017, 14: 2831-2837.
[13] Zhang Z, Qian W, Wang S, et al. Analysis of lncRNA-associated ceRNA network reveals potential lncRNA biomarkers in human colon adeno carcinoma[J]. Cell Physiol Biochem, 2018, 49: 1778-1791.
[14] Zhu G, Pei L, Xia H, et al. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer[J]. Mol Cancer, 2021, 20: 143. doi: 10.1186/s12943-021-01441-4.
[15] Duan B, Zhou X, Zhang X, et al. BRD4-binding enhancer promotes CRC progression by interacting with YY1 to activate the Wnt pathway through upregulation of TCF7L2[J]. Biochem Pharmacol, 2023, 218: 115877. doi: 10.1016/j.bcp.2023.115877.